Biocon: What's in the genes? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Biocon: What's in the genes?

Sep 1, 2004

Biocon is India's largest Biotechnology company with presence in biopharmaceuticals, enzymes, custom research and clinical research. Biocon evolved from being an enzyme producer in to a biopharmaceuticals by leveraging on its fermentation strength. The company was one of the first few Indian companies that seized the opportunity that was there in the bio-pharmaceutical space. Even though it is currently focused on biopharma products; it is still the largest enzymes producer in the country. The major source of revenues for Biocon is Statins, which constituted 57% of its consolidated revenues in FY04, of which, Simvastatin, the second largest selling statins in the world constitute about one-third of the company's statins sales. The largest selling statin in the world, Atorvastatin, is not a big contributor to the company's revenue as the molecule is still under patent cover in the major markets of US and Europe.

Currently the company is focussing on the anti-diabetic segment and immunosuppressants, which are going to be the focus areas for the company in future. Company has invested close Rs 3 bn in establishing a production facility for human insulin, which will be another focus area for the company. Company has also entered in an agreement with Bristol Myers Squibb for the supply of human insulin. The Supply will start in the last quarter of the current financial year. Apart from that Biocon has launched several products in the Indian markets in anti-diabetic and cardiovascular therapeutic segments.

Biocon also has a strong R&D initiative which has help it in patenting a fermentation process technology named PlaFactor which manufactures most of its fermentation based products. This gives us an idea that the company is serious on the R&D front. At present the company has 167 patent application fillings out of which 14 have received approval. Most of the approvals that company has relates to manufacturing processes of several products such as statins. Apart from in-house R&D, company has established two subsidiaries to carry out custom research and clinical research for third parties. The custom research business has shown growth in last two years and going forward this initiative can be a key growth driver.

Currently, the stock is trading at 42x its FY04 earning, which seems to be very high compared to its peers in the pharmaceutical sector, but given the growth prospects and the quality of management it can be said that this number to some extent is justified. Also another boost that can come in the growth of the company is in FY07 when Simvastatin, which has sales of about US$ 4 bn will come off patent. However in the short to medium-term, we believe, immunosuppressants and anti -diabetic products will drive the growth for the company.

Equitymaster requests your view! Post a comment on "Biocon: What's in the genes?". Click here!

  

More Views on News

BIOCON Announces Quarterly Results (2QFY22); Net Profit Up 4.9% (Quarterly Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

For the quarter ended September 2021, BIOCON has posted a net profit of Rs 2 bn (up 4.9% YoY). Sales on the other hand came in at Rs 18 bn (up 5.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON 2020-21 Annual Report Analysis (Annual Result Update)

Aug 10, 2021 | Updated on Aug 10, 2021

Here's an analysis of the annual report of BIOCON for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of BIOCON . Also includes updates on the valuation of BIOCON .

BIOCON Announces Quarterly Results (1QFY22); Net Profit Down 4.0% (Quarterly Result Update)

Jul 26, 2021 | Updated on Jul 26, 2021

For the quarter ended June 2021, BIOCON has posted a net profit of Rs 2 bn (down 4.0% YoY). Sales on the other hand came in at Rs 18 bn (up 3.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Dec 3, 2021 (Close)

TRACK BIOCON

BIOCON - AJANTA PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS